Overview

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This study is looking at outcomes in people with advanced cancers who have exhausted standard treatment options and are accessing off indication or unregistered drugs or combinations of drugs through compassionate access from the manufacturer.
Phase:
N/A
Details
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Treatments:
Atezolizumab
Dabrafenib
Nivolumab
Olaparib
Palbociclib
Pembrolizumab
Talazoparib
Trametinib
Vemurafenib